Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

AVR vs PMI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PMI Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)

PMI Overall Winner 6-Pillar Tally: AVR 1 – 4 PMI (1 Tie) Matrix Metrics: AVR 2 – 6 PMI

As of Nov 19, 2026, Picard Medical, Inc. (PMI) is the stronger overall head-to-head candidate over Anteris Technologies Global Corp. (AVR) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVR carries a Unified Composite Score of 46.4/100 (HOLD) at $5.09 (N/M Forward P/E, -4880.4% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin).

  • Technical & Structure Timing Caution: AVR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.5); meanwhile PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVR vs PMI
AVR NASDAQ
Anteris Technologies Global Corp. Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$5.09
-2.3% 1D
Market Cap $507.9M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 1.57β · 78% Vol
Unified Composite Score
46.4 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 57.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.8%), weak momentum, RSI 36
RSI-14: 35.5 · SMA20: $5.79 · SMA50: $6.70
PMI NYSE American Head-to-Head Winner
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap $17.1M
TTM Revenue $6.3M
Forward P/E N/M
Beta / 30D Vol 54.06β · 134% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.1 · SMA20: $7.55 · SMA50: $7.62

6-Pillar Scorecard Institutional Category Breakdown (AVR 1 – 4 PMI)

Columns: Metric · AVR · PMI
1. Valuation Multiples PMI
Forward P/E N/M N/M
Trailing P/E N/M 2.9x
PEG Ratio N/M N/M
EV / Revenue 125.1x 3.2x
2. Growth & Scale PMI
Revenue Growth (YoY) +21.0% +38.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.3M $6.3M
Market Cap $507.9M $17.1M
3. Profitability & Quality PMI
Gross Margin 75.8% 18.6%
Operating Margin -4880.4% -248.1%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -93.3% 0.0%
4. Balance Sheet & Cash Flow AVR
Cash Generation (TTM) -$94M -$17M
Cash Flow Margin N/A N/A
Net Cash / Leverage $216M Net Cash $3.2M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PMI
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 172.2% (82nd %ile) N/A (N/A)
Put/Call OI Skew 75.56x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVR (2) vs PMI (6)
Institutional Metric AVR PMI Criterion Row Edge
Market Capitalization
Scale
$507.9M $17.1M Larger Scale AVR
Trailing P/E Ratio
Valuation
N/M 2.9x Lower Multiple PMI
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+21.0% +38.6% Higher Growth PMI
Operating Margin (TTM)
Profitability
-4880.4% -248.1% Higher Margin PMI
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-93.3% 0.0% Higher ROE PMI
52-Week Range Position
Momentum
23% ($3–$11) 34% ($0–$18) Stronger Trend PMI
Beta / 30D Volatility
Risk Regime
1.57β · 78% Vol 54.06β · 134% Vol Lower Realized Risk AVR
Unified Institutional Score
Composite Signal
46.4 / 100 (HOLD) 48.4 / 100 (HOLD) Higher Composite PMI
Trailing 12M Revenue (USD)
Operating Scale
$2.3M $6.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.8% 18.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 125.1x EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$94M ($216M Net Cash) -$17M ($3.2M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVR +19.27 pp
AVR: -15.31% · PMI: -34.58%
3M Horizon PMI +139.58 pp
AVR: -43.32% · PMI: +96.26%
6M Horizon PMI +3463.36 pp
AVR: -24.03% · PMI: +3439.33%
1Y Horizon PMI +103.02 pp
AVR: +45.01% · PMI: +148.03%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AVR Revenue PMI Revenue AVR Op. Margin PMI Op. Margin Margin Leader
FY2024 $0M $0M -2899.4% -312.3% PMI
FY2025 $0M $0M -4908.2% -268.4% PMI

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVR BREAKDOWN
104d in phase · OBV DISTRIBUTION
Current IV 172.2%
IV Percentile 82nd %ile
Put/Call OI Skew 75.56x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact AVR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PMI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $507.9M market capitalization and -4880.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PMI Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AVR vs PMI Key Questions & Quantitative Answers

As of Nov 19, 2026, Picard Medical, Inc. (PMI) is the stronger overall head-to-head candidate over Anteris Technologies Global Corp. (AVR) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVR carries a Unified Composite Score of 46.4/100 (HOLD) at $5.09 (N/M Forward P/E, -4880.4% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin). Technical & Structure Timing Caution: AVR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.5); meanwhile PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PMI leads the Growth & Scale pillar: AVR posts +21.0% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (75.8% gross margin, -4880.4% operating margin), compared with PMI at +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin). Across the 2-period historical trajectory (FY2024 to FY2025), AVR cumulative revenue shifted N/A while PMI shifted N/A. In operating R&D and SG&A reinvestment, AVR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PMI.

PMI screens cheaper on headline valuation multiples. AVR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 125.1x EV/Revenue (unreported FCF margin), whereas PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVR (-93.3% ROE) versus PMI (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AVR carries 172.2% implied volatility (82nd %ile, Extreme (>80th %ile)), a 75.56x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.57β · 78% Vol realized risk). By comparison, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.